Australia is carefully awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://andrewjksg583928.blogoscience.com/49585532/this-new-drug-retatrutide-australia-a-promising-breakthrough-for-obesity-treatment